FDA
-
-
-
-
-
-
-
Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $32 at H.C. Wainwright
-
-
-
-
-
-
-
FDA places clinical hold on REGENXBIO gene therapies after tumor case
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
REGENXBIO receives FDA review extension for MPS II gene therapy
-
-
-
-
-
-
-
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
-
-
-
-
-
-
-
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

